Skip to Main Content

Author Details

Thoralf Lange
Hospital Weissenfels
1994
106
38
PMIDPaper TitleJournal TitlePublished Year
35987926Impact of the changing landscape of induction therapy prior to autologous stem cell transplantation in 540 newly diagnosed myeloma patients: a retrospective real-world study.J Cancer Res Clin Oncol2023
35181744Prospective phase II study of preemptive chimerism-driven reduction of immunosuppression after non-myeloablative conditioning-Eudract #: 2007-002420-15.Bone Marrow Transplant2022
32672489No advantage of Imatinib in combination with hydroxyurea over Imatinib monotherapy: a study of the East German Study Group (OSHO) and the German CML study group.Leuk Lymphoma2020
31937894Correction: Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1.Leukemia2020
31669230Comparison of Real-Time Quantitative PCR and Digital Droplet PCR for BCR-ABL1 Monitoring in Patients with Chronic Myeloid Leukemia.J Mol Diagn2020
30504903Clinical impact of clonal hematopoiesis in acute myeloid leukemia patients receiving allogeneic transplantation.Bone Marrow Transplant2019
31723806Prognostic Impact of Blood <i>MN1</i> Copy Numbers Before Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia.Hemasphere2019
30882891Circulating cKIT and PDGFRA DNA indicates disease activity in Gastrointestinal Stromal Tumor (GIST).Int J Cancer2019
30347270Optimized Digital Droplet PCR for BCR-ABL.J Mol Diagn2019
30262560Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma.Haematologica2019
29335621Prognostic relevance of DNMT3A R882 mutations in AML patients undergoing non-myeloablative conditioning hematopoietic stem cell transplantation.Bone Marrow Transplant2018
30042412Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions.Leukemia2018
30036739Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial.Eur J Cancer2018
29381150Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.Leukemia2018
29707154Similar expression profiles in CD34<sup>+</sup> cells from chronic phase chronic myeloid leukemia patients with and without deep molecular responses to nilotinib.Oncotarget2018
29785446Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients.Ann Hematol2018
28074067Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.Leukemia2017
28133783Prognostic impact of the CD34+/CD38- cell burden in patients with acute myeloid leukemia receiving allogeneic stem cell transplantation.Am J Hematol2017
28348390Donor cell leukemia: evidence for multiple preleukemic clones and parallel long term clonal evolution in donor and recipient.Leukemia2017
28368377Prognostic impact of the European LeukemiaNet standardized reporting system in older AML patients receiving stem cell transplantation after non-myeloablative conditioning.Bone Marrow Transplant2017
29152132High <i>BAALC</i> copy numbers in peripheral blood prior to allogeneic transplantation predict early relapse in acute myeloid leukemia patients.Oncotarget2017
28534173Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV).J Cancer Res Clin Oncol2017
28828689Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077).J Cancer Res Clin Oncol2017
26696465Favorable outcome in children and adolescents with a high proportion of advanced phase disease using single/multiple autologous or matched/mismatched allogeneic stem cell transplantations.Ann Hematol2016
27753609Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial.Ann Oncol2016
25036192A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR.Leukemia2015
26361971Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.Lancet Oncol2015
26369986Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib.Leukemia2015
26129640Comparable outcome after single-antigen-mismatched versus matched unrelated donor haematopoietic cell transplantation.J Cancer Res Clin Oncol2015
26202608JAK2V617F molecular remission in a primary myelofibrosis patient treated with ruxolitinib.Ann Hematol2015
25922062Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).Ann Oncol2015
25976868Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma.J Cancer Res Clin Oncol2015
25652737Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia.Leukemia2015
23964650Low tumor burden is associated with early B-cell reconstitution and is a predictor of favorable outcome after non-myeloablative stem cell transplant for chronic lymphocytic leukemia.Leuk Lymphoma2014
25085357A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation.Haematologica2014
25132497BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.Cancer Cell2014
24710567Value of liver elastography and abdominal ultrasound for detection of complications of allogeneic hemopoietic SCT.Bone Marrow Transplant2014
24292520Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib.Bone Marrow Transplant2014
23065514The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia.Haematologica2013
23833305Detection of mutant free circulating tumor DNA in the plasma of patients with gastrointestinal stromal tumor harboring activating mutations of CKIT or PDGFRA.Clin Cancer Res2013
23692564Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077.Br J Haematol2013
23543457Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells.Blood2013
23223358BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.Blood2013
23300178JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse.Haematologica2013
21818112Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients.Leukemia2012
22251158Bcr-Abl dependent post-transcriptional activation of NME2 expression is a specific and common feature of chronic myeloid leukemia.Leuk Lymphoma2012
22230800Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia.Leukemia2012
22421058Delayed processing of bone marrow samples reveals a prognostic pattern of NME mRNA expression in cytogenetically normal acute myeloid leukemia.Leuk Lymphoma2012
21132022The impact of the age of HLA-identical siblings on mobilization and collection of PBSCs for allogeneic hematopoietic cell transplantation.Bone Marrow Transplant2011
22156452Reduced-intensity conditioning in allogeneic stem cell transplantation for hematological malignancies: a historical perspective.Onkologie2011
  • 1 - 50 of 106

Recommended Authors

Sawa Ito
University of Pittsburgh
Career Start Year 2013
Number of shared co-authors 0
Hein Than
Singapore General Hospital
Career Start Year 2012
Number of shared co-authors 14
Friedrich St??lzel
University Hospital TU Dresden
Career Start Year 2008
Number of shared co-authors 11
Thomas K??hnke
Cancer Institute, Stanford University School of Medicine
Career Start Year 2008
Number of shared co-authors 3
Felicitas Thol
Hannover Medical School
Career Start Year 2007
Number of shared co-authors 7
Paulo Vidal Campregher
Hospital Israelita Albert Einstein
Career Start Year 2007
Number of shared co-authors 1
Thomas Cluzeau
Universite Nice Cote d'azur, CHU de Nice
Career Start Year 2005
Number of shared co-authors 4
Marlise R Luskin
Dana-Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 12
Tara L Lin
University of Kansas Medical Center
Career Start Year 2004
Number of shared co-authors 11
Jean-Baptiste Micol
INSERM U7, Universite Paris-Saclay
Career Start Year 2004
Number of shared co-authors 5
Raphael Itzykson
Universite Paris Cite, INSERM, CNRS
Career Start Year 2004
Number of shared co-authors 5
Daniel A Pollyea
University of Colorado Division of Hematology
Career Start Year 2004
Number of shared co-authors 16
Ronan Swords
Oregon Health and Science University
Career Start Year 2004
Number of shared co-authors 14
Vivian G Oehler
Fred Hutchinson Cancer Center.
Career Start Year 2003
Number of shared co-authors 14
Ivan Pasic
Princess Margaret Cancer Centre
Career Start Year 2001
Number of shared co-authors 0
Christopher S Hourigan
and Blood Institute, National Institutes of Health
Career Start Year 2001
Number of shared co-authors 16
Emmanuel Raffoux
Universite Paris Diderot
Career Start Year 1998
Number of shared co-authors 6
Farhad Ravandi
University of Texas M.D. Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 11
Bruno C Medeiros
AbbVie Inc.
Career Start Year 1996
Number of shared co-authors 14
David A Rizzieri
Duke University Medical Center
Career Start Year 1995
Number of shared co-authors 5
Michael Heuser
Hannover Medical School
Career Start Year 1993
Number of shared co-authors 11
Derek L Stirewalt
Fred Hutchinson Cancer Center
Career Start Year 1992
Number of shared co-authors 13
Gautam Borthakur
MD Anderson Cancer Center
Career Start Year 1992
Number of shared co-authors 10
Peter Westervelt
Washington University School of Medicine
Career Start Year 1990
Number of shared co-authors 4
Daniel J DeAngelo
Dana-Farber Cancer Institute
Career Start Year 1989
Number of shared co-authors 17
Jerald P Radich
Fred Hutchinson Cancer Center
Career Start Year 1989
Number of shared co-authors 28
Robert H Collins
University of Texas Southwestern Medical Center
Career Start Year 1987
Number of shared co-authors 15
Richard M Stone
Dana Farber Cancer Institute
Career Start Year 1986
Number of shared co-authors 22
Herv?? Dombret
Institut de Recherche Saint-Louis, Universite de Paris
Career Start Year 1984
Number of shared co-authors 8
Robin Fo??
Sapienza University.
Career Start Year 1968
Number of shared co-authors 4

Collaborators

Dietger Niederwieser
University of Leipzig
Co-authored papers 59
Michael W Deininger
University of Utah Huntsman Cancer Institute
Co-authored papers 24
Brian J Druker
Oregon Health & Science University
Co-authored papers 12
Richard T Maziarz
Oregon Health & Science University
Co-authored papers 8
Stephanie G Willis
OHSU Cancer Institute
Co-authored papers 6
Thomas O'Hare
Huntsman Cancer Institute, University of Utah
Co-authored papers 5
Thomas Ernst
Universitatsklinikum Jena
Co-authored papers 4
Christopher A Eide
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 4
Sandra Otto
Co-authored papers 3
Anthony D Pomicter
Huntsman Cancer Institute, University of Utah
Co-authored papers 3
Christina A Harrington
Oregon Health & Science University
Co-authored papers 3
Effie W Petersdorf
Fred Hutchinson Cancer Center
Co-authored papers 3
Lucy C Crossman
Oregon Health & Science University Cancer Institute
Co-authored papers 3
Matthew S Zabriskie
University of Utah
Co-authored papers 2
Ines Kovacs
Co-authored papers 2
Mary MacPartlin
Oregon Health and Science University
Co-authored papers 2
Eric P Stoffregen
Lewis-Clark State College
Co-authored papers 2
Anna M Eiring
Texas Tech University Health Sciences Center at El Paso
Co-authored papers 2
Richard D Press
Oregon Health and Science University
Co-authored papers 2
Jamshid S Khorashad
Institute of Cancer Research
Co-authored papers 2
Jennifer L Snead
University of New Mexico Health Sciences Center
Co-authored papers 2
Nikolas von Bubnoff
University Hospital of Schleswig-Holstein
Co-authored papers 2
Ann-Kathrin Eisfeld
The Ohio State University Comprehensive Cancer Center
Co-authored papers 2
Marc M Loriaux
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 2
Shannon K McWeeney
Oregon Health & Science University, University of California Berkeley
Co-authored papers 2
Shadmehr Demehri
Massachusetts General Hospital and Harvard Medical School
Co-authored papers 2
Stephen G O'Brien
Newcastle University
Co-authored papers 2
Byung Park
Oregon Health & Science University
Co-authored papers 2
Yaron Turpaz
Pte. Ltd.
Co-authored papers 1
Jorge Cortes
Georgia Cancer Center
Co-authored papers 1
Release 1.2